<a href="https://laohu8.com/S/NNVC">NanoViricides Inc.</a> Announces New Compensation Agreements, Extends President Dr. Anil Diwan's Contract with $400,000 Salary and Equity Incentives
NanoViricides Inc. has announced updated employment agreements for two key executives. Dr. Anil R. Diwan will continue as President under a contract extension effective July 1, 2025, and has been granted 10,204 shares of Series A Preferred Stock, vesting quarterly from September 30, 2025, through June 30, 2026. Should Dr. Diwan be terminated without cause, he will receive six months' salary as severance along with continued benefits. Chief Financial Officer Meeta Vyas has also extended her contract for one year starting July 1, 2025, maintaining her monthly base compensation of $10,800 and 129 shares of Series A Preferred Stock per month. Additionally, Ms. Vyas will now be reimbursed for up to 50% of her health insurance costs, capped at $2,500 per month.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-095676), on October 01, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.